Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its plans to release financial results for the third quarter ended September 30, 2024. The results will be published before trading begins on Friday, November 1, 2024. Following the release, Biodesix management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide a general business update.
Interested parties can register for the webcast through a provided link. Analysts wishing to participate in the question and answer session should use a separate link. A replay of the webcast will be made available on the company's investor website approximately two hours after the call concludes. Participants are advised to join the call 15 minutes before the start time.
Biodesix, Inc. (Nasdaq: BDSX), una delle principali aziende di soluzioni diagnostiche focalizzate sulle malattie polmonari, ha annunciato i suoi piani per pubblicare i risultati finanziari per il terzo trimestre chiuso il 30 settembre 2024. I risultati saranno pubblicati prima dell'inizio delle contrattazioni di venerdì 1 novembre 2024. Dopo la pubblicazione, il management di Biodesix condurrà una conference call e un webcast alle 8:30 ora orientale dello stesso giorno per discutere dei risultati finanziari e fornire un aggiornamento generale sull'attività.
Le parti interessate possono registrarsi per il webcast tramite un link fornito. Gli analisti che desiderano partecipare alla sessione di domande e risposte dovrebbero utilizzare un link separato. Una registrazione del webcast sarà disponibile sul sito web per gli investitori dell'azienda circa due ore dopo la conclusione della chiamata. Si consiglia ai partecipanti di unirsi alla chiamata 15 minuti prima dell'orario di inizio.
Biodesix, Inc. (Nasdaq: BDSX), una de las principales empresas de soluciones diagnósticas centradas en enfermedades pulmonares, ha anunciado sus planes para publicar resultados financieros del tercer trimestre cerrado el 30 de septiembre de 2024. Los resultados se publicarán antes de que comiencen las operaciones el viernes 1 de noviembre de 2024. Tras la publicación, la dirección de Biodesix llevará a cabo una conferencia telefónica y transmisión web a las 8:30 a.m. hora del Este el mismo día para discutir los resultados financieros y proporcionar una actualización general del negocio.
Las partes interesadas pueden registrarse para la transmisión web a través de un enlace proporcionado. Los analistas que deseen participar en la sesión de preguntas y respuestas deben utilizar un enlace separado. Una repetición de la transmisión web estará disponible en el sitio web de inversores de la empresa aproximadamente dos horas después de que finalice la llamada. Se aconseja a los participantes unirse a la llamada 15 minutos antes de la hora de inicio.
Biodesix, Inc. (Nasdaq: BDSX)는 폐 질환에 중점을 둔 주요 진단 솔루션 회사로, 2024년 9월 30일에 종료된 3분기 재무 결과 발표 계획을 발표했습니다. 결과는 2024년 11월 1일 금요일 거래 시작 전에 발표될 예정입니다. 발표 후, Biodesix 경영진은 같은 날 동부 표준시 기준 오전 8시 30분에 컨퍼런스 콜 및 웹캐스트를 진행하여 재무 결과를 논의하고 일반 사업 업데이트를 제공합니다.
관심 있는 분들은 제공된 링크를 통해 웹캐스트에 등록할 수 있습니다. 질문 및 답변 세션에 참여하고자 하는 분석가는 별도의 링크를 사용해야 합니다. 통화가 종료된 후 약 2시간 후에 회사의 투자자 웹사이트에서 웹캐스트의 재생이 제공될 것입니다. 참여자는 시작 15분 전에 통화에 참여하는 것이 좋습니다.
Biodesix, Inc. (Nasdaq: BDSX), une entreprise de solutions diagnostiques de premier plan spécialisée dans les maladies pulmonaires, a annoncé ses intentions de publier les résultats financiers du troisième trimestre clôturé le 30 septembre 2024. Les résultats seront publiés avant l'ouverture des marchés le vendredi 1er novembre 2024. Après la publication, la direction de Biodesix organisera une conférence téléphonique et un webinaire à 8h30, heure de l'Est le même jour pour discuter des résultats financiers et fournir une mise à jour générale sur l'entreprise.
Les parties intéressées peuvent s'inscrire au webinaire via un lien fourni. Les analystes souhaitant participer à la session de questions et réponses doivent utiliser un lien séparé. Un enregistrement du webinaire sera disponible sur le site web des investisseurs de l'entreprise environ deux heures après la fin de l'appel. Les participants sont conseillés de se joindre à l'appel 15 minutes avant l'heure de début.
Biodesix, Inc. (Nasdaq: BDSX), ein führendes Unternehmen für diagnostische Lösungen, das sich auf Lungenerkrankungen spezialisiert hat, hat seine Pläne bekannt gegeben, die Finanzergebnisse für das dritte Quartal zum 30. September 2024 zu veröffentlichen. Die Ergebnisse werden vor Handelsbeginn am Freitag, den 1. November 2024 veröffentlicht. Nach der Veröffentlichung wird das Management von Biodesix am gleichen Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und ein allgemeines Geschäftsupdate zu geben.
Interessierte Parteien können sich über einen bereitgestellten Link für den Webcast registrieren. Analysten, die an der Frage-und-Antwort-Runde teilnehmen möchten, sollten einen separaten Link verwenden. Eine Wiederholung des Webcasts wird ungefähr zwei Stunden nach Abschluss des Gesprächs auf der Investoren-Website des Unternehmens verfügbar sein. Teilnehmer werden geraten, sich 15 Minuten vor Beginn der Sitzung einzuwählen.
- None.
- None.
Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, expectations regarding revenue and margin growth and its impact on profitability, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241018266313/en/
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
(339) 970-2843
Source: Biodesix, Inc.
FAQ
When will Biodesix (BDSX) release its Q3 2024 financial results?
What time is Biodesix's (BDSX) Q3 2024 earnings call scheduled for?
How can investors access Biodesix's (BDSX) Q3 2024 earnings webcast?
What period does Biodesix's (BDSX) upcoming financial report cover?
